Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Saved in:
| Title: | Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. |
|---|---|
| Authors: | Gallagher L; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Xiao J; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Hsueh J; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Shah S; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Danner M; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Zwart A; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Ayoob M; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Yung T; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Simpson T; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Fallick M; Medical Science Department, Myovant Sciences, Inc, United States., Kumar D; Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States., Leger P; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Dawson NA; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States., Suy S; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States., Collins SP; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2023 Oct 17; Vol. 13, pp. 1289249. Date of Electronic Publication: 2023 Oct 17 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37916156 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gallagher+L%22">Gallagher L</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Xiao+J%22">Xiao J</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Hsueh+J%22">Hsueh J</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Shah+S%22">Shah S</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Danner+M%22">Danner M</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Zwart+A%22">Zwart A</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Ayoob+M%22">Ayoob M</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Yung+T%22">Yung T</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Simpson+T%22">Simpson T</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Fallick+M%22">Fallick M</searchLink>; Medical Science Department, Myovant Sciences, Inc, United States.<br /><searchLink fieldCode="AU" term="%22Kumar+D%22">Kumar D</searchLink>; Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States.<br /><searchLink fieldCode="AU" term="%22Leger+P%22">Leger P</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Dawson+NA%22">Dawson NA</searchLink>; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Suy+S%22">Suy S</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Collins+SP%22">Collins SP</searchLink>; Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2023 Oct 17; Vol. 13, pp. 1289249. <i>Date of Electronic Publication: </i>2023 Oct 17 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37916156 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2023.1289249 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1289249 Titles: – TitleFull: Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gallagher L – PersonEntity: Name: NameFull: Xiao J – PersonEntity: Name: NameFull: Hsueh J – PersonEntity: Name: NameFull: Shah S – PersonEntity: Name: NameFull: Danner M – PersonEntity: Name: NameFull: Zwart A – PersonEntity: Name: NameFull: Ayoob M – PersonEntity: Name: NameFull: Yung T – PersonEntity: Name: NameFull: Simpson T – PersonEntity: Name: NameFull: Fallick M – PersonEntity: Name: NameFull: Kumar D – PersonEntity: Name: NameFull: Leger P – PersonEntity: Name: NameFull: Dawson NA – PersonEntity: Name: NameFull: Suy S – PersonEntity: Name: NameFull: Collins SP IsPartOfRelationships: – BibEntity: Dates: – D: 17 M: 10 Text: 2023 Oct 17 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 13 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |
